SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA-mutant tumours

Published 2016 View Full Article

Authors

Keywords

Journal

ANNALS OF ONCOLOGY

Volume 27, Issue suppl_6, Pages -

Publisher

Oxford University Press (OUP)

Online

2017-02-04

DOI

10.1093/annonc/mdw365.92

Ask authors/readers for more resources

Add your recorded webinar

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started

ANNALS OF ONCOLOGY

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Add your recorded webinar

Ask a Question. Answer a Question.